Abstract:Transarterial chemoembolization (TACE) is an image-guided locoregional therapy used for the treatment of patients with primary hepatocellular carcinoma (HCC). However, conventional TACE formulations such as epirubicin-lipiodol emulsion are rapidly dissociated due to the instability of the emulsion, result-ing in insufficient local drug concentrations in the target tumor. To overcome these limitations, we used biodegradable Idarubicin loaded microspheres (BILMs), which were prepared from gelatin and car-rageenan and could be loaded with Idarubicin (IDA-MS). The morphology and the ability to load and release IDA of BILMs were characterized in vitro. We evaluated tumor changes and side effects after TACE treatment with IDA-MS in VX2 rabbit and C57BL/6 mice HCC models. In addition, the effect of IDA-MS on the tumor immune microenvironment of HCC tumors was elucidated via mass spectrometry and im-munohistochemistry. Result showed that IDA-MS was developed as a new TACE formulation to overcome the poor delivery of drugs due to rapid elimination of the anticancer drug into the systemic circulation. We demonstrated in rabbits and mice HCC models that TACE with IDA-MS resulted in significant tumor shrinkage and no more severe adverse events than those observed in the IDA group. TACE with IDA-MS could also significantly enhance the sensitivity of anti-PD1 immunotherapy, improve the expression of CD8+ T cells, and activate the tumor immune microenvironment in HCC. This study provides a new approach for TACE therapy and immunotherapy and illuminates the future of HCC treatment.Conventional transarterial chemoembolization (TACE) formulations are rapidly dissociated due to the in-stability of the emulsion, resulting in insufficient local drug concentrations in hepatocellular carcinoma (HCC). To overcome these limitations, we used biodegradable microspheres called BILMs, which could be loaded with Idarubicin (IDA-MS). We demonstrated in rabbits and mice HCC models that TACE with IDA-MS resulted in significant tumor shrinkage and no more severe adverse events than those observed in the IDA group. TACE with IDA-MS could also significantly enhance the sensitivity of anti-PD1 immunotherapy, improve the expression of CD8+ T cells, and activate the tumor immune microenvironment in HCC. This study provides a new approach for TACE therapy and immunotherapy and illuminates the future of HCC treatment.(c) 2022 The Author(s). Published by Elsevier Ltd on behalf of Acta Materialia Inc. This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ )

A Study on Overcoming Post‐TACE Drug Resistance in HCC Based on Controllable Oxygen Release‐Magnetic Hyperthermia Therapy

HIF-2α-targeted interventional chemoembolization multifunctional microspheres for effective elimination of hepatocellular carcinoma

Superstable Homogeneous Iodinated Formulation Technology: Revolutionizing Transcatheter Arterial Chemoembolization

Transarterial Chemoembolization with Drug-Eluting Beads for the Treatment of Hepatocellular Carcinoma:Recent Progress in Research

Targeting metabolic reprogramming promotes the efficacy of transarterial chemoembolization in the rabbit VX2 liver tumor model

Recent advances and applications of microspheres and nanoparticles in transarterial chemoembolization for hepatocellular carcinoma

Idarubicin-loaded Degradable Hydrogel for TACE Therapy Enhances Anti-Tumor Immunity in Hepatocellular Carcinoma

TACE by using microspheres and lipiodol for the treatment of hepatocellular carcinoma: analysis of short-term efficacy

Enhanced radiotherapy efficacy and induced anti-tumor immunity in HCC by improving hypoxia microenvironment using oxygen microcapsules

Microspheres-mediated Magnetic Thermal Ablation Combined with Immune Checkpoint Blockade Therapy for Liver Cancer

Gelation Embolism Agents Suppress Clinical TACE-incited Pro-Metastatic Microenvironment Against Hepatocellular Carcinoma Progression.

Periodic mesoporous organosilica-coated magnetite nanoparticles combined with lipiodol for transcatheter arterial chemoembolization to inhibit the progression of liver cancer

Homogenous multifunctional microspheres induce ferroptosis to promote the anti-hepatocarcinoma effect of chemoembolization

Super‐Stable Homogeneously Sustained‐Release System Mediates Transcatheter Arterial Ionic‐Embolization Strategy for Hepatocellular Carcinoma Therapy

The blooming intersection of transcatheter hepatic artery chemoembolization and nanomedicine

High-Performance Poly(lactic-co-glycolic Acid)-Magnetic Microspheres Prepared by Rotating Membrane Emulsification for Transcatheter Arterial Embolization and Magnetic Ablation in VX2 Liver Tumors.

Liquid metal microspheres with an eddy-thermal effect for magnetic hyperthermia-enhanced cancer embolization-immunotherapy

Reprogramming Of Glucose Metabolism For Revisiting Hepatocellular Carcinoma Resistance To Transcatheter Hepatic Arterial Chemoembolization

Idarubicin-loaded Biodegradable Microspheres Enhance Sensitivity to Anti-Pd1 Immunotherapy in Transcatheter Arterial Chemoembolization of Hepatocellular Carcinoma.

Procoagulant CaCO3-embedded embolic microspheres can potentiate transcatheter arterial embolization of hepatocellular carcinoma

Doxorubicin-Loaded UiO-66/Bi2S3 Nanocomposite-Enhanced Synergistic Transarterial Chemoembolization and Photothermal Therapy Against Hepatocellular Carcinoma.